Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    KD025-213
Previous Study | Return to List | Next Study

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03640481
Recruitment Status : Active, not recruiting
First Posted : August 21, 2018
Last Update Posted : September 16, 2019
Sponsor:
Information provided by (Responsible Party):
Kadmon Corporation, LLC

Brief Summary:
This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy

Condition or disease Intervention/treatment Phase
Chronic Graft-versus-host-disease Drug: KD025 Phase 2

Detailed Description:

Phase 2, open label, randomized, multicenter study in subjects with cGVHD who have previously been treated with at least 2 prior lines of systemic therapy. Approximately 126 subjects with active cGVHD will be randomized (1:1) to receive treatment with one of two KD025 regimens:

  • Arm A: KD025 200mg QD
  • Arm B: KD025 200mg BID

Randomization will be stratified according to prior cGVHD treatment with ibrutinib (Yes / No) and severe cGVHD at baseline (Yes / No). Subjects may receive treatment in 28-day treatment cycles until clinically significant progression of cGVHD. Subjects who have not achieved a response after 12 cycles of KD025 should be withdrawn if in the Investigator's judgment there is no evidence of clinical benefit. Subjects will undergo evaluations as outlined in the Study Assessments table. The primary endpoint is the overall response rate (ORR) with responses as defined by the 2014 National Institute of Health (NIH) Consensus Development Project on clinical trials in cGVHD.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 126 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Phase 2, open label, randomized, multicenter study in subjects with cGVHD who have previously been treated with at least 2 prior lines of systemic therapy
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of KD025 in Subjects With Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy (The ROCKstar Study)
Actual Study Start Date : October 15, 2018
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : January 2022


Arm Intervention/treatment
Experimental: Arm A: KD025 200mg QD
Eligible subjects randomized to arm A will take KD025 200mg once daily
Drug: KD025
KD025 is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.

Experimental: Arm B: KD025 200mg BID
Eligible subjects randomized to arm B will take KD025 200mg twice daily
Drug: KD025
KD025 is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.




Primary Outcome Measures :
  1. Overall Response Rate (ORR) [ Time Frame: 6 months ]
    The primary endpoint is the ORR with responses as defined by the 2014 National Institute of Health (NIH) Consensus Development Project on clinical trials in cGVHD.


Secondary Outcome Measures :
  1. Duration of Response (DOR) [ Time Frame: 6 months ]
    The time from initial response of PR or CR until documented progression of cGVHD

  2. Change in Lee Symptom Scale Score [ Time Frame: 6 months ]
    Analyses will include: Number of subjects with a ≥7 point reduction, Number of subjects with a ≥7 point reduction on 2 consecutive assessments and Duration of a ≥7 point reduction. Symptom burden will be assessed on Day 1 of each cycle starting on Cycle 1 Day 1, as well as at the EOT visit. The questionnaire asks subjects to indicate the degree of bother that they experienced due to symptoms in seven domains potentially affected by chronic GVHD (skin, eyes, mouth, breathing, eating and digestion, energy, and emotional distress). The response will be determined based on clinician assessment specifically for each of affected organ as a Complete Response, Partial Response or Progression.

  3. Response rate by organ system [ Time Frame: 6 months ]
    The response assessment for the nine individual organs (Skin, Eyes, Mouth, Esophagus, Upper GI, Lower GI, Liver, Lungs, and Joints and fascia).

  4. Percentage of subjects who have a best response of PR or CR [ Time Frame: 6 months ]
  5. Change in corticosteroid dose [ Time Frame: 6 months ]
  6. Change in calcineurin inhibitor dose [ Time Frame: 6 months ]
  7. Failure-free survival (FFS) [ Time Frame: 6 months ]
    FFS is defined as the absence of cGVHD treatment change, non-relapse mortality and recurrent malignancy. Median FFS (from first dose of KD025) and landmark FFS at 1 year will be analyzed.

  8. Overall Survival (OS) [ Time Frame: 6 months ]
    Time from first dose of KD025 to the date of death due to any cause.

  9. Change in cGVHD severity as based on the Physician-reported global cGVHD Activity Assessment [ Time Frame: 6 months ]
    Physician-reported outcome

  10. Change in symptom activity as based on cGVHD Activity Assessment Patient Self-Report [ Time Frame: 6 months ]
    Patient-reported outcome

  11. Determine the Peak Plasma Concentration (Cmax) of KD025 [ Time Frame: Pre-dose and post-dose sampling within 12 hours. ]
    Determine the maximum plasma concentration (Cmax) of KD025

  12. Determine the observed time to reach peak plasma concentration (Tmax) of KD025 [ Time Frame: Pre-dose and post-dose sampling within 12 hours. ]
    The time that KD025 reach the maximum plasma concentration (Tmax).

  13. Determine the half-life (T1/2) of KD025 [ Time Frame: Pre-dose and post-dose sampling within 12 hours. ]
    The time it takes for half of KD025 to be removed from plasma by biological processes (T1/2)

  14. Determine the area under the plasma concentration versus time curve (AUC) of KD025 [ Time Frame: Pre-dose and post-dose sampling within 12 hours. ]
    Area under the plasma concentration versus time curve (AUC)

  15. Time to Response [ Time Frame: 6 months ]
    The time it takes to obtain a cGVHD response to KD025.

  16. Time to next treatment [ Time Frame: 6 months ]
    The time it takes to initiate a new systemic cGVHD treatment after starting KD025.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female subjects at least 12 years of age who have had allogenic hematopoietic cell transplant (HCT).
  2. Previously received at least 2 and not more than 5 lines of systemic therapy for cGVHD
  3. Receiving glucocorticoid therapy with a stable dose over the 2 weeks prior to screening
  4. Have persistent cGVHD manifestations and systemic therapy is indicated
  5. Karnofsky Performance Score of ≥ 60 (if aged 16 years or older); Lansky Performance Score of ≥ 60 (if aged < 16 years)
  6. Weight ≥ 40kg

Exclusion Criteria:

  1. Subject has not been on a stable dose / regimen of systemic cGVHD treatments for at least 2 weeks prior to screening. (Note: Concomitant corticosteroids, calcineurin inhibitors, sirolimus, MMF, methotrexate, rituximab, and extracorporeal photophoresis (ECP) are acceptable. Systemic investigational GVHD treatments are not permitted).
  2. Histological relapse of the underlying cancer or post-transplant lymphoproliferative disease at the time of screening.
  3. Current treatment with ibrutinib. Prior treatment with ibrutinib is allowed with a washout of at least 28 days prior to randomization.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03640481


  Show 33 Study Locations
Sponsors and Collaborators
Kadmon Corporation, LLC

Layout table for additonal information
Responsible Party: Kadmon Corporation, LLC
ClinicalTrials.gov Identifier: NCT03640481     History of Changes
Other Study ID Numbers: KD025-213
First Posted: August 21, 2018    Key Record Dates
Last Update Posted: September 16, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Graft vs Host Disease
Immune System Diseases